Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Surgery Subjects Clear all
Terminated Not applicable Interventional

Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections

NCT00203541
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
TELFA™ A.M.D. Island dressing
Device
Lead sponsor
Tyco Healthcare Group
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2007 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol

NCT00678834
View directory record Official record
Conditions
End Stage Cardiac Failure, Pulmonary Failure, End Stage Liver Disease, Morbid Obesity, Recalcitrant Epilepsy Requiring Surgery, Healthy Subjects
Interventions
To surgery patients, Tocopherol capsules., Tocotrienol to healthy subjects., To surgery patients, Tocotrienol capsules.
Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Jun 26, 2026, 4:26 AM EDT
Terminated No phase listed Observational

Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury

NCT01547065
View directory record Official record
Conditions
Subjects Undergoing Cardiac or Major Surgery Where TEE is Used as a Matter of Routine
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Jun 26, 2026, 4:26 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery

NCT01765270
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
45 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

NCT00888940
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
Ecallantide, Cyklokapron(R)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

NCT02891837
View directory record Official record
Conditions
Acute Lung Injury
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Loma Linda, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jun 26, 2026, 4:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

NCT06730828
View directory record Official record
Conditions
Atrial Fibrillation, Postoperative
Interventions
The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Combination Product
Lead sponsor
Helios Cardio Inc.
Industry
Eligibility
20 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

NCT01777165
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
ABT-719, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Danbury, Connecticut • Gainesville, Florida • Jacksonville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

NCT00838383
View directory record Official record
Conditions
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Interventions
sitaxsentan (Thelin), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
48 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jun 26, 2026, 4:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
View directory record Official record
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 3 Interventional

Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

NCT06021457
View directory record Official record
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Huntsville, Alabama • La Jolla, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

NCT00816023
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
ecallantide, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Jun 26, 2026, 4:26 AM EDT
Suspended Phase 2Phase 3 Interventional

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

NCT00038454
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Hemolink (hemoglobin raffimer IV solution)
Drug
Lead sponsor
Hemosol
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 4:26 AM EDT
Not yet recruiting Not applicable Interventional

Effect of PEEP on Cardiac Function

NCT07531602
View directory record Official record
Conditions
Cardiac Surgery Subjects
Interventions
EIT Guided PEEP Trial
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 26, 2026, 4:26 AM EDT
Active, not recruiting No phase listed Observational

WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise

NCT06576050
View directory record Official record
Conditions
Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jun 26, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Results available

Rapid Sternal Closure System (TALON)

NCT00638014
View directory record Official record
Conditions
Sternal Wound Infection, Mediastinitis
Interventions
Rapid Sternal Closure System, Conventional wire closure
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Jun 26, 2026, 4:26 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL, bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
0 Years to 6 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 26, 2026, 4:26 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

NCT01602328
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AC607, Vehicle Only
Biological
Lead sponsor
AlloCure Inc.
Industry
Eligibility
21 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Progel Vascular Sealant

NCT01959503
View directory record Official record
Conditions
Aortic Valve Stenosis, Aneurysm of Ascending Aorta, Aortic Valve Disorder, Bicuspid Valve Disorder
Interventions
Progel Vascular Sealant, Gelfoam Plus
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

NCT00600483
View directory record Official record
Conditions
Cardiac Surgery, Sternal Wound Infection
Interventions
gentamicin-collagen sponge dipped in saline
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
1,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 26, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

NCT02610283
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
QPI-1002, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jun 26, 2026, 4:26 AM EDT
Active, not recruiting Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR), Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Hollywood, California • La Jolla, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 4:26 AM EDT